Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Practical and ethical issues with genetic screening.

John E Wagner1

  • 1University of Minnesota, Box 366 UMHC, 420 Delaware Street, SE, Minneapolis, MN 55455, USA. wagne002@maroon.tc.umn.edu

Hematology. American Society of Hematology. Education Program
|November 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CSF GAG non-reducing ends in MPS IH after peripheral and brain-penetrating therapies: A model comparing IV non-targeted ERT and HCT.

Molecular therapy. Advances·2026
Same author

Tracking Cytopenias in <i>FANCA</i>-deficient Fanconi Anemia.

medRxiv : the preprint server for health sciences·2025
Same author

BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

American journal of human genetics·2025
Same author

Research Communication: Prevalence of Asymptomatic Premalignant Oesophageal Lesions in Patients With Fanconi Anaemia.

Alimentary pharmacology & therapeutics·2025
Same author

G-quadruplexes as a source of vulnerability in BRCA2<i>-</i>deficient granule cell progenitors and medulloblastoma.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.

Journal for immunotherapy of cancer·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

New genetic testing offers powerful insights for hematologists but requires careful consideration of medical, legal, and ethical implications to ensure accurate patient care and avoid misinterpretation.

Area of Science:

  • Genomics and Precision Medicine
  • Clinical Hematology
  • Medical Ethics

Background:

  • Hematologists face an increasing number of genetic-based diagnostic tools.
  • Genetic testing is advancing rapidly, reaching technical frontiers like single-cell analysis for preimplantation genetic diagnosis.
  • The proliferation of these tests necessitates a comprehensive understanding of their implications.

Purpose of the Study:

  • To highlight the evolving landscape of genetic testing in clinical hematology.
  • To underscore the need for validation of new genetic diagnostic tools.
  • To inform hematologists about the multifaceted considerations surrounding genomic-based medicine.

Main Methods:

  • Review of current advancements in genetic testing technologies relevant to hematology.

Related Experiment Videos

  • Analysis of potential challenges including technical limitations and data interpretation.
  • Discussion of the medical, legal, ethical, and social dimensions of genetic testing.

    • Main Results:

    • Genetic tests are becoming more sophisticated, enabling earlier disease risk identification.
    • Technical limitations and the potential for misdiagnosis or misinterpretation are significant concerns.
    • The integration of genomic medicine requires hematologists to address broader patient implications.

    Conclusions:

    • Hematologists must be aware of the medical-legal landscape of genetic testing.
    • Psychological, ethical, and social factors are critical in the adoption of genomic-based medicine.
    • Proactive engagement with these issues is essential for responsible clinical practice.